Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Gold is SOARING - here's what you need to do]( Everything is lining up perfectly for a historic gold bull run. One gold expert says he's found the best way to get in, for just $5. [Click here for full details.]( --------------------------------------------------------------- December 27, 2023 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"]( The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. [Get the name of the stock here ]( --------------------------------------------------------------- [Elicio Therapeutics]( Ticker: [ELTX]( Recent Price: $7.10 Average Analyst Price Target: $12.00 (69.01%) Market Cap: $54.23M Role Transaction Description No. of Shares Amount Date Director, >10% Owner Informative Buy Non Open Market Buy 1,213,000 $7,047,530 2 Days Ago Recent Analyst Action: Robert Burns, analyst at H.C. Wainwright, reiterates coverage on [Elicio Therapeutics (ELTX)]( in the Healthcare sector with a Buy rating and a price target of $12 (1 month ago). Here are 3rd party ratings for [ELTX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 27% (68 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [U.S. Government Secretly Preparing for World War III?]( take a moment to[click here and see this official congressional report…]( Because it proves our government is secretly preparing for World War III... Which could help trigger the biggest financial crisis in America’s history. In fact… A former VP of a major investment bank has just warned that millions of unprepared Americans could be wiped out. [Click here to see the details and learn how to prepare.]( --------------------------------------------------------------- [Syros Pharmaceuticals]( Ticker: [SYRS]( Recent Price: $7 Average Analyst Price Target: $20.00 (185.71%) Market Cap: $182.83M Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 904,977 $3,999,998 2 Days Ago Recent Analyst Action: Leah R., analyst at Brookline Capital Markets, reiterates coverage on [Syros Pharmaceuticals (SYRS)]( in the Healthcare sector with a Buy rating and a price target of $37 (22 hours ago). Here are 3rd party ratings for [SYRS](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Sell, Top 27% (68 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Verrica Pharmaceuticals]( Ticker: [VRCA]( Recent Price: $6.50 Average Analyst Price Target: $11.80 (88.46%) Market Cap: $286.88M Role Transaction Description No. of Shares Amount Date >10% Owner Informative Buy Non Open Market Buy 504,652 $3,256,191 2 Days Ago >10% Owner Informative Buy Non Open Market Buy 1,233,931 $6,941,716 9 Days Ago Recent Analyst Action: Oren Livnat, analyst at H.C. Wainwright, reiterates coverage on [Verrica Pharmaceuticals (VRCA)]( in the Healthcare sector with a Buy rating and a price target of $12 (1 month ago). Here are 3rd party ratings for [VRCA](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 30% (75 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [HighPeak Energy]( Ticker: [HPK]( Recent Price: $14.74 Average Analyst Price Target: $23.07 (-32.16%) Market Cap: $1.85B Role Transaction Description No. of Shares Amount Date CEO,Director, >10% Owner Informative Buy Non Open Market Buy 150,442 $2,162,268 2 Days Ago Recent Analyst Action: Neal Dingmann, analyst at Truist Financial, reiterates coverage on [HighPeak Energy (HPK)]( in the Energy sector with a Sell rating and a price target of $10 (1 month ago). Here are 3rd party ratings for [HPK](: - TipRanks.com: Moderate Sell - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 19% (205 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Kirby]( Ticker: [KEX]( Recent Price: $80.79 Average Analyst Price Target: $96.00 (20.06%) Market Cap: $4.78B Role Transaction Description No. of Shares Amount Date President-Kirby Inland Marine Informative Buy Non Open Market Buy 6,861 $469,979 2 Days Ago President-Kirby Engine Systems Informative Buy Non Open Market Buy 3,876 $265,506 9 Days Ago Recent Analyst Action: Ken Hoexter, analyst at Bank of America Securities, reiterates coverage on [Kirby (KEX)]( in the Industrials sector with a Buy rating and a price target of $94 (1 month ago). Here are 3rd party ratings for [KEX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 24% (60 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Wall Streets “King of Quants” Warns: “We’ve Created a Monster”]( One of the world’s top investors has issued a dire warning… A.I. will eat jobs, destroy businesses and crush stock portfolios starting around January 2024. It doesn’t matter if you have $500 or $5 million… You need to make these [three critical moves]( right now… or risk losing everything. --------------------------------------------------------------- [Kimbell Royalty Partners]( Ticker: [KRP]( Recent Price: $15.29 Average Analyst Price Target: $21.80 (30.80%) Market Cap: $2.87B Role Transaction Description No. of Shares Amount Date Director Informative Buy Non Open Market Buy 30,000 $460,757 2 Days Ago Recent Analyst Action: Derrick Whitfield, analyst at Stifel Nicolaus, reiterates coverage on [Kimbell Royalty Partners (KRP)]( in the Energy sector with a Buy rating and a price target of $21 (4 weeks ago). Here are 3rd party ratings for [KRP](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Strong Sell, Bottom 3% (245 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [NioCorp Developments]( Ticker: [NB]( Recent Price: $3.25 Average Analyst Price Target: $12.00 (269.23%) Market Cap: $106.29M Role Transaction Description No. of Shares Amount Date Chief Financial Officer Informative Buy Non Open Market Buy 9,360 $29,999 5 Days Ago Chief Executive Officer Informative Buy Non Open Market Buy 46,801 $149,997 5 Days Ago Non-Executive, Director Informative Buy Non Open Market Buy 78,003 $250,000 6 Days Ago Recent Analyst Action: Heiko Ihle, analyst at H.C. Wainwright, reiterates coverage on [NioCorp Developments (NB)]( in the Basic Materials sector with a Buy rating and a price target of $12 (2 months ago). Here are 3rd party ratings for [NB](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Bottom 40% (151 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Hidden AI Stock Surge]( Don't miss out on this hidden AI stock surge for a billion dollar opportunity! [>> Discover the AI Pickaxe <<]( --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software